雷替曲塞联合奥沙利铂治疗晚期胃癌的疗效观察  

Curative effect observation of raltitrexed combined with oxaliplatin in the treatment of advanced gastric cancer

作　　者：程燕[1] 周恒根[1] 刘兰芳[1] 倪敬中[1] 李亚莉[1] 

机构地区：[1]江苏省邳州市人民医院肿瘤内科,221399

出　　处：《中国现代药物应用》2015年第5期16-18,共3页Chinese Journal of Modern Drug Application

摘　　要：目的分析探讨雷替曲塞联合奥沙利铂治疗晚期胃癌的疗效及安全性。方法 50例胃癌患者随机分为两组,观察组25例采用雷替曲塞联合奥沙利铂化疗方案;对照组25例采用奥沙利铂+亚叶酸钙+5-氟尿嘧啶化疗方案。比较两组疗效。结果观察组总有效率和疾病控制率均高于对照组,两组比较差异有统计学意义(P<0.05);观察组与对照组不良反应发生率分别为24.0%和32.0%,差异无统计学意义(P>0.05);两组未见因不良反应延缓化疗的患者,且无化疗相关性死亡。结论雷替曲塞联合奥沙利铂治疗晚期胃癌临床疗效较好,是治疗晚期胃癌的一种较好的联合化疗方案,值得临床使用。Objective To analyze and investigate the curative effect and safety of raltitrexed combined with oxaliplatin in the treatment of advanced gastric cancer. Methods A total of 50 patients with gastric cancer were randomly divided into two groups. The observation group with 25 cases received rahitrexed combined with oxaliplatin for chemotherapy; the control group with 25 cases was treated by oxaliplatin＋calcium folinate＋5-flu- orouracil for chemotherapy. Curative effects were compared between the two groups. Results The total effective rate and disease control rate were all higher in the observation group than in the control group, and the difference between the two groups had statistical significance （P〈0.05）. The incidences of adverse reactions were respectively 24.0% and 32.0% in the observation groupand the control group, and the difference was not statistically signifi- cant （P〉0.05）. There was no patient with suspended chemotherapy due to adverse reactions, or related death case with chemotherapy. Conclusion The combination of raltitrexed and oxaliplatin has good clinical effect in the treatment of advanced gastric cancer. It is a remarkable combined chemotherapy method for advanced gastric can- cer, and is worthy of clinical application.

关 键 词：雷替曲塞 奥沙利铂 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]